Gastritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

The Gastritis pipeline drugs market research report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects.

Gastritis Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Gastritis pipeline drugs market are Prostaglandin E Synthase, 5-Hydroxytryptamine Receptor 3, Bacterial Cell Wall, Free Radical, Gastrin/Cholecystokinin Type B Receptor, Interleukin 5 Receptor Subunit Alpha, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K.

Gastritis Pipeline Drugs Market Analysis, by Targets

For more Gastritis pipeline drugs market target insights, download a free report sample

Gastritis Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the Gastritis pipeline drugs market are Prostaglandin E Synthase Inhibitor, 5-Hydroxytryptamine Receptor 3 Antagonist, Bacterial Cell Wall Disruptor, Free Radical Scavenger, Gastrin/Cholecystokinin Type B Receptor Antagonist, Interleukin 5 Receptor Subunit Alpha Antagonist, and Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/KInhibitor.

Gastritis Pipeline Drugs Market Analysis, by Mechanism of Actions

 For more mechanism of action insights into the Gastritis pipeline drugs market, download a free report sample

Gastritis Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Gastritis pipeline drugs market are oral, intravenous, nasal, parenteral, subcutaneous, and topical.

Gastritis Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Gastritis pipeline drugs market, download a free report sample

Gastritis Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Gastritis pipeline drugs market are Small Molecule and Monoclonal Antibody.

Gastritis Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Gastritis pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Gastritis pipeline drugs market are Addpharma Inc, GNT Pharma Co Ltd, Recce Pharmaceuticals Ltd, CalyGene Biotechnology Inc, Daewon Pharmaceutical Co Ltd, and Daewoong Co Ltd.

Gastritis Pipeline Drugs Market Analysis, by Companies

To know more about the Gastritis pipeline drugs market companies, download a free report sample

Gastritis Pipeline Drugs Market Report Overview

Scope

This report provides:

• A snapshot of the global therapeutic landscape of Gastritis.
• Reviews of pipeline therapeutics for Gastritis by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• Reviews key companies involved in Gastritis therapeutics and enlist all their major and minor projects.
• Evaluation of Gastritis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• All the dormant and discontinued pipeline projects.
• Reviews of the latest news related to pipeline therapeutics for Gastritis.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gastritis.
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding the Gastritis pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.